Dimerix Limited

DXB

AU000000DXB7

Biotechnology & Medical Research

Market Closed - Australian S.E. 09:10:10 25/09/2026 +03			5-day change	1st Jan Change
0.2250 ^AUD	-4.26%		-8.16%	-59.09%

09-23	Dimerix Receives AU$17 Million in Proceeds After Completing Initial Drawdown Under Non-Dilutive Funding Facility	MT
09-21	Dimerix Limited(ASX:DXB) dropped from S&P/ASX All Ordinaries Index	CI

Dimerix Appoints CFO

Published on 01/21/2026 at 01:24 am +03

MT Newswires

This article is reserved for our members.

Continue with Google Continue with Apple Continue with LinkedIn

or by email

Continue with an email.

Latest news about Dimerix Limited

09-23	Dimerix Receives AU$17 Million in Proceeds After Completing Initial Drawdown Under Non-Dilutive Funding Facility	MT
09-21	Dimerix Limited(ASX:DXB) dropped from S&P/ASX All Ordinaries Index	CI
09-14	Dimerix Says Mexican Composition of Matter Patent Granted for Drug Candidate	MT
09-04	Dimerix Reaches Major Milestone With AU$34 Million Non-Dilutive Loan Facility, Euroz Hartleys Says	MT
09-04	Dimerix Secures AU$34 Million in Non-Dilutive Loan Facility Agreements; Shares Up 4%	MT
08-27	Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2026	CI
08-20	Dimerix Receives Initial $10 Million Upfront Payment Under Everest Medicines License Deal; Shares Gain 4%	MT
08-17	Dimerix Completes Transfer of Acute Kidney Injury Drug Candidate's US Investigational New Drug Application, Shares Up 6%	MT
07-23	Dimerix Secures US Patent Regarding Kidney Injury Drug Candidate, Shares Jump 4%	MT
07-17	Dimerix Limited and Mission Therapeutics Limited Expand Pipeline with Acquisition of Phase 2 Ready Asset for Acute Kidney Injury	CI
07-17	Dimerix Hits 'Major Milestone' With AU$10 Million Financing Package, Euroz Hartleys Says	MT
07-17	Dimerix Acquires Therapeutic Asset from UK-Based Firm; Shares Up 8%	MT
07-17	Dimerix Secures AU$10 Million Loan Facility From Substantial Shareholder Associate; Shares Up 9%	MT
07-09	Dimerix Expands Post-Trial Access to Kidney Disorder Drug for Eligible Patients	MT
06-17	Dimerix's Everest Deal Adds Value, Eases Funding Concerns, Euroz Hartleys Says	MT

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.

Employees

Sector

Biotechnology & Medical Research

More about the company